324 related articles for article (PubMed ID: 27977334)
1. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
[TBL] [Abstract][Full Text] [Related]
3. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
[TBL] [Abstract][Full Text] [Related]
4. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
Connell WT; Hong J; Liao W
Front Immunol; 2021; 12():815121. PubMed ID: 35154085
[TBL] [Abstract][Full Text] [Related]
6. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
[No Abstract] [Full Text] [Related]
8. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
10. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
12. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
13. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
14. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
15. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study.
Borghi A; Rizzo R; Corazza M; Bertoldi AM; Bortolotti D; Sturabotti G; Virgili A; Di Luca D
Dermatol Ther; 2014; 27(5):284-9. PubMed ID: 24909182
[TBL] [Abstract][Full Text] [Related]
16. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
17. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
[TBL] [Abstract][Full Text] [Related]
18. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
19. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Belmonte C; Cabaleiro T; Román M; Ochoa D; Talegón M; Saiz-Rodríguez M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 May; 18(7):631-638. PubMed ID: 28470127
[TBL] [Abstract][Full Text] [Related]
20. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
